Acacia Pharma's twice spurned drug finally makes the FDA cut
Third time’s the charm for Acacia Pharma.
The Cambridge, UK-based company on Thursday finally secured FDA approval for its treatment for patients with postoperative nausea & vomiting (PONV), who are symptomatic despite having received prophylactic treatment.
The drug, an intravenous formulation of the selective dopamine D2 and D3 antagonist amisulpride, was shown to help patients in four positive pivotal clinical trials by 2017. But manufacturing troubles repeatedly hobbled the company’s quest to get the therapy — branded Barhemsys — on to the US market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.